GIPR and obesity due to melanocortin 4 receptor deficiency: However, as co-agonist and tri-agonist GIPR-based therapies have shown reductions in body weight and improvement in lipid profiles in cellular, mouse, and human models, ongoing research opens many doors for understanding the underlying metabolic processes and developing therapies to address the health concerns of obesity and T2DM.